• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Pfizer Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    4/28/25 4:24:01 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PFE alert in real time by email
    pfe-20250424
    0000078003false00000780032024-04-252024-04-250000078003us-gaap:CommonStockMember2024-04-252024-04-250000078003pfe:NotesDue20271.000Member2024-04-252024-04-25

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549

    FORM 8-K

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): April 24, 2025

    PFIZER INC.
    (Exact name of registrant as specified in its charter)
    Delaware1-361913-5315170
    (State or other(Commission File(I.R.S. Employer
    jurisdiction ofNumber)Identification No.)
    incorporation)  
    66 Hudson Boulevard East10001-2192
    New York, New York (Zip Code)
    (Address of principal executive offices)

    Registrant’s telephone number, including area code:
    (212) 733-2323

    (Former name or former address, if changed since last report)


    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $.05 par valuePFENew York Stock Exchange
    1.000% Notes due 2027PFE27New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐







    Item 5.07 Submission of Matters to a Vote of Security Holders
    (a) The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 24, 2025.
    (b) Shareholders voted on the matters set forth below.
    1. The nominees for election to the Company’s Board of Directors set forth in Item 1 to the Company’s Proxy Statement filed with the U.S. Securities and Exchange Commission on March 13, 2025 were elected to hold office until the Company’s next Annual Meeting of Shareholders, based upon the following votes:
    Nominee
    Votes For      
    Votes Against
    Abstentions
    Broker non-vote
    Ronald E. Blaylock3,429,698,773137,851,88613,621,435954,654,621
    Albert Bourla3,246,800,234307,245,70027,123,033954,654,621
    Mortimer J. Buckley3,465,158,857102,427,54313,584,534954,654,621
    Susan Desmond-Hellmann3,448,290,762117,666,67015,212,701954,654,621
    Joseph J. Echevarria3,173,957,929393,321,22813,891,403954,654,621
    Scott Gottlieb3,500,030,43569,733,81911,402,546954,654,621
    Susan Hockfield3,503,463,76465,146,65512,561,991954,654,621
    Dan R. Littman3,411,026,726156,668,04913,478,088954,654,621
    Shantanu Narayen3,485,062,34582,853,61113,251,147954,654,621
    Suzanne Nora Johnson3,340,830,762228,079,26312,262,263954,654,621
    James Quincey3,429,352,443138,236,12113,570,566954,654,621
    James C. Smith3,341,701,230226,092,58013,378,736954,654,621
    Cyrus Taraporevala3,462,368,536105,107,79813,690,897954,654,621
    2. The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2025 fiscal year was approved based upon the following votes:
    Votes for approval
    4,216,654,548
    Votes against
    300,423,270
    Abstentions
    18,745,406
    Broker non-votes
    n/a
    3. The proposal to approve, on an advisory basis, the 2025 compensation of the Company's Named Executive Officers was approved based upon the following votes:
    Votes for approval
    1,947,064,397
    Votes against
    1,612,203,678
    Abstentions
    21,901,539
    Broker non-votes
    954,654,621





    4. The shareholder proposal to Adopt Shareholder Vote Regarding Golden Parachutes was not approved based upon the following votes:
    Votes for approval
    338,488,044
    Votes against
    3,208,877,595
    Abstentions
    33,777,457
    Broker non-votes
    954,654,621
    5. The shareholder proposal to Issue A Report Evaluating The Risks Related To Religious Discrimination Against Employees was not approved based upon the following votes:
    Votes for approval
    71,070,282
    Votes against
    3,448,108,236
    Abstentions
    61,979,369
    Broker non-votes
    954,654,621







    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     PFIZER INC.
       
       
    Dated: April 28, 2025By:/s/ Margaret M. Madden
     Margaret M. Madden
      Senior Vice President and Corporate Secretary
      Chief Governance Counsel
       


    Get the next $PFE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PFE

    DatePrice TargetRatingAnalyst
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    12/10/2024$29.00Neutral
    BofA Securities
    11/15/2024$25.00Underperform
    Wolfe Research
    10/25/2024$30.00Neutral
    Citigroup
    10/17/2024$32.00Mkt Perform
    Bernstein
    8/7/2024Neutral → Outperform
    Daiwa Securities
    3/22/2024Buy → Hold
    Argus
    2/23/2024$36.00Buy
    Guggenheim
    More analyst ratings